Navigation Links
Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
Date:7/9/2008

Orexigen is the only company with two late-stage product candidates to

address a broad spectrum of obesity patients

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced today that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company's two late-stage obesity product candidates. The trial is designed to build on highly encouraging safety and efficacy results from a previous Phase IIb trial of Empatic, which demonstrated robust weight loss at 48 weeks ranging from approximately 11 percent to 15 percent in obese patients completing the trial and a discontinuation rate due to adverse events that was not significantly different than placebo.

"Initiation of ZB-202 is an important milestone for our Empatic program and the final anticipated step before moving into Phase III development," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Empatic continues to be an important component of the Company's obesity program. Along with Contrave(R), now in Phase III clinical trials, these product candidates both have the potential to target a large, distinct and complementary segment within the obesity market."

Orexigen is the only company currently developing two late-stage product candidates to address the full spectrum of obesity ranging from mild-to-moderate and moderate-to-severe obesity. Obesity has become a national epidemic, with more than 70 million Americans classified as obese and 300,000 deaths a year attributable to obesity, according to the Centers for Disease Control (CDC). Obesity is associated with a number of significant medical conditions, including diabetes, hypertension, high cho
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
2. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
3. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
4. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
5. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
6. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
7. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
10. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Yesterday, former Congressman ... device manufacturing facility. Rep. Kennedy and Dick ... facilitate cutting-edge research in neurological disease and treatment. ... health advocate, Garen Staglin , created One ... fundamental changes that will radically accelerate the development ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Nov. 4, 2010 Valeant Pharmaceuticals International, Inc. (NYSE: ... the Company,s Board of Directors (the "Board") has declared ... (the "Special Dividend") that shareholders of record as of ... "Record Date") will be entitled to receive on December ...
... Cardiogenesis Corporation (OTCQB: CGCP), a leading developer of surgical ... disease, today reported financial results for its third quarter ... Revenue for the third quarter of 2010 was ... revenue of $2,134,000.  Gross margin was 84% for the ...
Cached Medicine Technology:Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 2Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 3Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan 4Cardiogenesis Reports Third Quarter 2010 Results 2Cardiogenesis Reports Third Quarter 2010 Results 3Cardiogenesis Reports Third Quarter 2010 Results 4Cardiogenesis Reports Third Quarter 2010 Results 5Cardiogenesis Reports Third Quarter 2010 Results 6
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Dubai is ... basketball legend is heading to the UAE. The ... champion will be in the UAE from 28-31 October ... in support of diabetes awareness. The event is being ... marketing and event management company based in Dubai. The ...
(Date:7/12/2014)... Seattle, Wa (PRWEB) July 12, 2014 ... by Doctors Sen and Samantha Pearson, a couple boasting ... chose to launch Restore My Vision Today as a ... that many ophthalmologists have become in their respective ... makes readers privy to a “secret” trove of pertinent ...
(Date:7/12/2014)... 2014 Ladies, it doesn't matter what your ... who are looking for an affordable gown can visit ... dresses) to get their dream items. Recently, the company has ... gowns . Along with that, it is also providing great ... special offer; the deadline of this promotion is July 29, ...
(Date:7/11/2014)... 2014 According to new report ... is expected to register a CAGR of 2.28% ... 71 market data tables and 76 figures spread ... Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will ... , The report provides market analysis of ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... Income Protection, Offers Tips for Obtaining Coverage , ARLINGTON, Va., ... survey show the historic recession has left many Americans with ... they are more vulnerable to serious financial hardship in the ... work. According to the nonprofit LIFE Foundation, more than a ...
... and Afghanistan ... To help ease the transition and readjustment challenges facing Iraq ... of America (IAVA) joined the Ad Council today to launch a ... Support Campaign. Launched on Veterans Day 2008, the first series of ...
... distinguished professor at Kansas State University,s Division of Biology, ... from The National Eye Institute of the National Institutes ... renewal will make Conrad,s grant the longest continuously funded ... years," said Jim Guikema, K-State associate vice president for ...
... of a statin in time of crisis improved long-term ... -- Giving patients a cholesterol-busting statin drug during a ... of longer-term problems, Czech researchers say. , The one-year ... than halved for people suffering life-threatening episodes of acute ...
... Data Presented at American Heart Association ATVB Conference Shows ... Lesions in Treated PatientsWASHINGTON and SAN FRANCISCO, May 1 ... today announced the results of a sub-study of patients ... who received serial 64 slice multidetector computed tomography (MDCT) ...
... Wash., May 1 SCOLR Pharma, Inc. (NYSE Amex: ... ended March 31, 2009. The Company will host a ... (Eastern Daylight Time).Bruce S. Morra, SCOLR Pharma,s President and CEO, ... our two lead product candidates, ibuprofen and pseudoephedrine, and the ...
Cached Medicine News:Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 2Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 3Health News:Hit Hard by the Economy, Americans Risk Knockout Without Disability Insurance 4Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 2Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 3Health News:Video: IAVA and Ad Council Build on Success of Groundbreaking Veterans Campaign with New Friends and Family Element 4Health News:K-State professor awarded $1.48 million to study LASIK complictions 2Health News:K-State professor awarded $1.48 million to study LASIK complictions 3Health News:Cholesterol Drugs May Help in Cardiac Emergency 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 2Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 3Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 4Health News:VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 2Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 3Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 4Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 5Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 6Health News:SCOLR Pharma, Inc. Reports First Quarter 2009 Financial Results 7
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: